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beneﬁ t for bevacizumab. However, in colorectal cancer, 
a larger pooled analysis of VEGF-A concentrations 
showed a prognostic beneﬁ t for this biomarker, but 
no predictive value for bevacizumab treatment.16 A 
biomarker for anti-angiogenic treatment in patients 
with gastrointestinal cancers remains elusive.
Although ramucirumab might oﬀ er hope as a sal-
vage treatment in patients with gastric cancer, is the 
modest beneﬁ t reported in REGARD likely to be shown 
in all patients with treatment failure after ﬁ rst-line 
therapy? Patients were selected on the basis of a fairly 
high per formance status and normal organ function. 
Gastric cancer is a highly aggressive disease with often 
rapid disease progression and clinical decline; therefore, 
the population in this study might not be indicative 
of all patients stopping initial therapy for metastatic 
disease. In view of the beneﬁ t reported for patients with 
high functional status in this trial, the potential role of 
ramucirumab as a maintenance strategy might be a topic 
for future investigation. We now await with anticipation 
reporting of the ongoing trials of ramu cirumab combined 
with chemotherapy in early lines of therapy.
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Although incidence rates of meningococcal disease 
in developed countries have steadily decreased over 
the past century, the disease remains a formidable 
public health threat in Africa. The geographical area 
most aﬀ ected has been named the meningitis belt 
and includes countries of the Sahel and sub-Sahel. 
New ﬁ ndings from the study by Doumagoum Daugla 
and colleagues1 in The Lancet conﬁ rm the eﬀ ective-
ness of one shot of a glycoconjugate vaccine 
(serogroup A meningococcal polysaccharide–tetanus 
toxoid conjugate vaccine [PsA–TT, MenAfriVac]), 
devel oped under the Meningitis Vaccine Project 
(MVP),2 against disease caused by and carriage of 
sero group A meningococci in Chad. These ﬁ ndings 
might ﬁ nally usher in the beginning of elimination of 
sero group A meningococci in the meningitis belt, an 
endeavour that seems theoretically possible in view of 
the huge success of conjugate vaccines in abolishing 
disease caused by serogroup C meningococci in 
England and other countries.3
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Despite the availability and use of polysaccharide 
vaccines for the control of outbreaks since the 1970s, 
epidemics caused by serogroup A have continued 
to recur in the meningitis belt with incidence rates 
during outbreaks surpassing 300 cases per 100 000 
population.4 Daugla and coworkers1 document the 
successful reduction of disease incidence by 94% after 
vaccination with PsA–TT, as compared with disease 
incidence in a region in which the vaccination campaign 
had not been carried out. Carriage prevalence of the 
epidemic strain was reduced by 98% after vaccination 
with PsA–TT. The vaccine’s eﬀ ect on carriage probably 
explains the absence of cases in residents too old (older 
than 30 years) or too young (younger than 1 year) to 
be immunised in vaccinated regions. The complete 
levelling of the expected rise in incidence in the ﬁ rst 
quarter of 2012 impressively underscores the potential 
of PsA–TT for areas aﬀ ected by serogroup A disease.
Results from studies in Burkina Faso, the ﬁ rst country to 
start vaccination in December 2010, have already shown 
reduction of disease incidence,5 elimination of carriage,6 
and a herd eﬀ ect5,6 after vaccination with PsA–TT. 
However, by contrast with Chad, the campaign in Burkina 
Faso targeted the whole population aged 1–29 years, 
resulting in the vaccination of more than 11 million people 
within 10 days.5 Nevertheless, as incidence rates were 
already falling sharply since 2007,5 the reported vaccine 
eﬀ ect might have been enhanced by natural waning of the 
disease. By contrast, the situation in Chad was diﬀ erent; 
here, regions vaccinated in December, 2011 included only 
part of the population (roughly 1·8 million people), while 
extension of enhanced surveillance to a non-vaccinated 
district (Moissala) allowed concurrent comparison of 
incidence between vaccinated and unvaccinated areas. 
The investigators do not detail whether the popula-
tions in vaccinated and unvaccinated areas were indeed 
comparable; additionally, they state that selection of 
respective areas was not random. However, because 
disease progression had been consistent in both areas 
before vaccination, the assumption that the populations 
were indeed similar is plausible. The presented study 
design1 allows a more accurate assessment of vaccine 
eﬀ ect than do designs with purely temporal controls.6,7
Daugla and colleagues’ study would not have been 
possible without the MVP, which exempliﬁ es how an 
infectious disease can be tackled without the help of 
multinational companies with little interest in entering 
markets oﬀ ering low proﬁ t margins. Although the MVP 
represents an innovative development programme 
between high-income and low-income countries, it 
also encourages collaboration between low-income 
countries—eg, between India as a producer and African 
countries as consumers of a biotechnology product. This 
new approach, worthy of replication and extension, was 
also honoured in the Brazil–Cuba meningitis project.8
The report further highlights the urgent need for high 
quality surveillance systems for the assessment of vaccine 
eﬀ ectiveness. However, establishment of high quality 
surveillance is very challenging, as shown by the inability 
of researchers, who report implementation of enhanced 
surveillance in the vaccinated and unvaccinated areas 
for the duration of the dry season, to estimate one of 
their system’s most basic properties: completeness 
of case ascertainment.1 Apart from measurement of 
vaccine eﬀ ect, surveillance systems should be able to 
warn about possible serogroup replacement.9 Although 
episodes of capsule switching have been reported in 
countries using vaccines against serogroup C,10,11 these 
episodes were generally not widespread or lasting. 
Nevertheless, because experience of elimination of 
serogroup A by glycoconjugate vaccines is limited, 
and capsule replacement was also shown for other 
bacteria including pneumococci,12 the establishment 
of surveillance systems needs to be prioritised. Further 
research should focus on the development and 
validation of serological correlates of protection and on 
the establishment of improved methods for detection 
of carriage,9 because exact duration of protection and 
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Understanding of adhesion formation after abdominal 
surgery and its unwanted eﬀ ects can be traced back to the 
advent of intra-abdominal surgery. Weibel and Majno1 
described the eﬀ ect of abdominal surgical interventions 
in post-mortem studies, noting abdominal adhesions in 
67% of patients who had previous abdominal surgery. 
Many subsequent studies have supported this ﬁ nding 
and indicated even higher rates of adhesion formation 
after abdominal surgery.
In an attempt to explain the pathogenesis of peri-
toneal adhesions, Schade and Williamson2 undertook 
ultra structural analysis of adhesions in rodents and 
con cluded that desquamation of mesothelial cells, 
leaving a denuded surface, seemed to be the critical 
event in adhesion formation. Subsequently, Buckman 
and col leagues3 thought that ﬁ brin was deposited 
on an exposed basement membrane, and failure to 
clear this deposited ﬁ brin due to local depression 
of plasminogen activator activity was the unifying 
mechanism of ab dominal ad hesion formation. 
Present understanding is that adhesion formation 
is a normal part of wound healing, with various 
factors determining either resolution or pathological 
adhesion formation.4
Schade and Williamson’s work2 formed the scientiﬁ c 
basis for changes in surgical techniques, which aim 
to reduce tissue handling and limit tissue damage 
and adhesion formation. To prevent intraperitoneal 
adhe sions after repeat laparotomies, intraperitoneal 
application of paraﬃ  n, camphor, air insuﬄ  ation, 
and amnion was recom mended by Kubanyl,5 who 
also pointed out that no reliable method to prevent 
abdominal adhesions existed. This pessimistic view 
resonates to the present day, and often leads to 
fatalistic acceptance of postoperative abdominal 
adhesion for mation rather than use of an active 
approach to reduce or prevent adhesions in routine 
surgical practice.6
Many drugs have been administered both topically and 
systemically in an attempt to reduce adhesion formation, 
Adhesion barriers for abdominal surgery: a sticky problem
age-stratiﬁ ed carriage prevalences are needed for the 
identiﬁ cation of optimum vaccination strategies.13
Although the paper by Daugla and colleagues1 
represents an important milestone in the battle against 
meningococcal disease, many more mysteries regarding 
meningococci await clariﬁ cation; thus, the jury remains 
out as to why serogroup A, prevalent in the northern 
hemisphere until the 1980s, has mostly disappeared 
from Europe,14 and why, with a few ephemeral excep-
tions,15 it has not been successfully reintroduced into 
industrialised countries despite frequent travel.
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